Novartis Invests €32 Million to Expand Torre Annunziata Campus

Novartis is ready to expand its Torre Annunziata manufacturing site. To do so, it has planned a total investment of €32 million in the Campania hub, aimed at creating a space dedicated to the development, innovation, and new technologies in the field of life sciences.

If you want to find more details about Novartis and the most recent investments the company made in Italy, download for free our companion app. The Born2Invest mobile app brings you the most important business news of the day so you can stay on top of the market.

The Novartis campus in Torre Annunziata represents one of the main industrial hubs in southern Italy

The expansion project, as reported in a company note, was recently approved by the commissioner for the Campania Special Economic Zone (SEZ) Giuseppe Romano. The goal of the plan is to reach more and more patients around the world by focusing on cutting-edge technologies and enhancing the production capacity of the campus.

The Novartis campus in Torre Annunziata represents one of the main industrial hubs in southern Italy specializing in the production of life-saving drugs mainly in the area of oncology, cardiovascular, and neuroscience for the whole world, with a strategic value for the Group globally.

“The Torre Annunziata site represents an achievement we are proud of” commented Valentino Confalone, managing director, and country president of Novartis Italy. “This new milestone reaffirms the importance of creating virtuous partnerships with local institutions to benefit the attractiveness and manufacturing growth of areas with high potential for technological development that can contribute to innovation in our industry.”

“The Torre Annunziata plant represents one of the group’s most strategic sites in the world for oral solid productions,” added Sabino Di Matteo, CEO of the Novartis Torre Annunziata Campus. “The quality and expertise of the site’s human resources, combined with substantial investments in technology and infrastructure, will enhance our ability to reach more and more of the world’s patients with essential and innovative medicines.”

In 2021, the Torre Annunziata plant was certified by the Fda, and in 2022 regulatory authorities approved production for the Chinese market, going on to consolidate the site’s production capacity, which in the last year exceeded 100 million packs per year and expected to prospectively reach nearly 150 million packs per year afferent to more than 118 markets worldwide.

Thanks to this investment plan, Novartis Italia, which already achieved a turnover of €1.72 billion in 2022, €78 million of which was obtained through exports, further strengthens its commitment to generating value and innovation in the main therapeutic areas in which it operates.

__

(Featured image by PublicDomainPictures via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.